First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA

The U.S. FDA has granted CRLX101 Orphan Drug designation for the treatment of ovarian cancer and Fast Track designation in combination with Avastin® in metastatic renal cell carcinoma.05/11/2016

Source: Kidney Cancer Association - May 11, 2016 Category: Urology & Nephrology Source Type: news